drugset / Trial / NCT01430013
Trial of Endostar Combined With CHOPT for T Cell Lymphoma
Phase 2
Unknown
30 enrolled
Tianjin Medical University Cancer Institute and Hospital
Simcere Pharmaceutical Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.
Timeline
- Start
- 2011-06
- Primary completion
- 2015-11
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Pirarubicin | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Teniposide | Small molecule | — | — |
| Background | Vincristine | Small molecule | — | — |